Cary Street Partners Asset Management’s Biogen BIIB Stock Holding History

Cary Street Partners Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30	Closed	-$8.34K	–	214
2023 Q1	$8.34K	Hold	30	–	–	﹤0.01%	346
2022 Q4	$8.31K	Buy	30 +15	+100%	+$4.24K	﹤0.01%	377
2022 Q3	$4K	Buy	+15	New	+$3.19K	﹤0.01%	374
2022 Q2	–	Sell	-4,981	Closed	-$1.05M	–	157
2022 Q1	$1.05M	Sell	4,981 -545	-10%	-$119K	0.21%	102
2021 Q4	$1.33M	Sell	5,526 -1,430	-21%	-$368K	0.28%	86
2021 Q3	$1.97M	Sell	6,956 -93	-1%	-$30.5K	0.69%	53
2021 Q2	$2.44M	Sell	7,049 -22,275	-76%	-$6.75M	0.58%	54
2021 Q1	$1.96M	Buy	29,324 +2,518	+9%	+$679K	0.48%	64
2020 Q4	$1.79M	Buy	+26,806	New	+$6.92M	0.53%	60

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cary Street Partners Asset Management's BIIB Position: Q2 2023 in Review

Cary Street Partners Asset Management sold out of Biogen (BIIB) in Q2 2023, closing a stake of 30 shares — an estimated $8.34K sold.

Cary Street Partners Asset Management first reported a position in BIIB in Q4 2020 and held it in 9 quarters. The position peaked at $2.44M in Q2 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

Cary Street Partners Asset Management reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
Cary Street Partners Asset Management sold 30 Biogen shares in Q2 2023, an estimated $8.34K.
Cary Street Partners Asset Management first reported a position in Biogen in Q4 2020 and held it in 9 quarters.
Cary Street Partners Asset Management's Biogen position peaked at $2.44M in Q2 2021.
1,009 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2023, filed 10 Aug 2023.